Arm Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Arm today announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of American depositary shares representing its ordinary shares. The size and price range for the proposed offering have yet to be determined. The initial public offering is subject to market and other conditions and the completion of the SEC’s review process.
This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "Securities Act"), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act and other applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230429005023/en/
Contact information
Media
Arm External Communications
Eliza Walsh (US)
eliza.walsh@arm.com
Alexandra Harrod (UK)
alexandra.harrod@arm.com
FGS Global
ArmLimited@FGSGlobal.com
Investor Relations
Arm IR
Ian Thornton
Ian.thornton@arm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Wins 6 Global InfoSec Awards at RSAC 2024, Named “Hot” Cybersecurity Company6.5.2024 19:10:00 EEST | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has won six Global InfoSec Awards from Cyber Defense Magazine at this year’s RSA Conference. Armis received the following accolades: Armis named “Hot Cybersecurity Company” Nadir Izrael, Armis’ Co-Founder and CTO, awarded “Cutting Edge Chief Technology Officer” Armis Centrix™ won multiple awards: “Cutting Edge” platform accolade in the Cyber Exposure Management category “Best Product” for Attack Surface Management “Next Gen” product for Vulnerability Prioritization and Remediation The Armis AI-powered Asset Intelligence Engine received a “Publisher’s Choice” award in the category recognizing AI Platforms for Cybersecurity Strategy Analytics “These accolades reinforce Armis’ dedication to innovation and our commitment to helping our customers solve their biggest cybersecurity problems through one comprehensive platform,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Armis will continue to push the boundari
Edgio Named Winner of the Coveted Global InfoSec Awards During RSA Conference 20246.5.2024 19:00:00 EEST | Press release
Edgio is proud to announce it has received the Web Application Security award from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine. According to Verizon’s Data Breach Investigation Report (DBIR), over 60% of data breaches were attributed to web applications, underscoring the urgent need for organizations to continuously manage threat exposure across their web applications and throughout the entire DevSecOps lifecycle. Committed to addressing the complex and evolving needs of organizations, Edgio continues to innovate and expand its services with its recent launch of Attack Surface Management (ASM) - a solution designed to discover all web assets, provide full inventory of technologies, detect security exposures and manage exposure response across an organization from a centralized management interface. ASM, coupled with Edgio’s holistic web security solutions and managed security services provide the industry’s first edge-enabled continuous
NetApp Appoints Market Growth and Revenue Operations Leader, Dallas Olson to Chief Commercial Officer Role6.5.2024 18:30:00 EEST | Press release
NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced Dallas Olson as the company’s new Chief Commercial Officer, reporting to NetApp’s President, César Cernuda. Olson brings over 25 years of experience building high-performance teams responsible for planning, operations, enablement, engagement, and go-to-market strategies. As NetApp’s CCO, Olson will oversee sales strategy driving business growth in key areas including AI and Keystone through specialist teams, enhance market presence, optimize sales models, foster strategic partnerships, champion a customer-centric approach, and drive initiatives to maintain NetApp’s position as a market leader primed for accelerated growth. “We’re thrilled for Dallas to join NetApp at a time of momentum for the company as we empower enterprises to make their data infrastructure intelligent with unified data storage built for innovation in the era of AI," said César Cernuda, President at NetApp. “Olson's previous achievem
Nanochon closes $4M Series Seed Prime6.5.2024 18:00:00 EEST | Press release
Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round. The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team. “We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.” Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilag
Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies6.5.2024 17:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland. The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies. “We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collabo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom